# MEDICATION POLICY: Pulmozyme®



Generic Name: Dornase alfa

Therapeutic Class or Brand Name: Pulmozyme

Applicable Drugs (if Therapeutic Class): N/A

Preferred: N/A

Non-preferred: N/A

**Date of Origin:** 2/1/2013

Date Last Reviewed / Revised: 1/5/2023

## PRIOR AUTHORIZATION CRITERIA

(May be considered medically necessary when criteria I through V are met)

- I. Documented diagnosis of Cystic Fibrosis.
- II. Documentation of a forced vital capacity (FVC) of  $\geq$  40% of predicted.
- III. Pulmozyme will be used concurrently with standard therapies for cystic fibrosis (eg, antimicrobials, bronchodilators, chest physiotherapy).
- IV. For requests with twice-daily dosing, there must be documented treatment failure on once-daily dosing.
- V. Treatment must be prescribed by or in consultation with a pulmonologist or a physician who specializes in the treatment of cystic fibrosis.
- VI. Refer to the plan document for the list of preferred products. If the requested agent is not listed as a preferred product, must have documented treatment failure or contraindication to the preferred product(s).

#### **EXCLUSION CRITERIA**

N/A

## OTHER CRITERIA

 The recommended dose for use in most cystic fibrosis patients is one 2.5 mg single-use ampule inhaled once daily using a recommended nebulizer. Some patients may benefit from twice daily administration.

## **QUANTITY / DAYS SUPPLY RESTRICTIONS**

- Once-daily dosing: One 30-unit carton per 30 days
- Twice-daily dosing: Two 30-unit cartons per 30 days

## **APPROVAL LENGTH**

• **Authorization:** 6 months.

## MEDICATION POLICY: Pulmozyme®



• **Re-Authorization:** An updated letter of medical necessity showing maintenance or improvement on medication.

## **APPENDIX**

N/A

## **REFERENCES**

- 1. Pulmozyme. Prescribing information. Genentech Inc; 2021. Accessed December 20, 2022. <a href="http://www.gene.com/download/pdf/pulmozyme\_prescribing.pdf">http://www.gene.com/download/pdf/pulmozyme\_prescribing.pdf</a>.
- 2. Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2013;187(7):680-689. doi:10.1164/rccm.201207-11600e

**DISCLAIMER:** Medication Policies are developed to help ensure safe, effective and appropriate use of selected medications. They offer a guide to coverage and are not intended to dictate to providers how to practice medicine. Refer to Plan for individual adoption of specific Medication Policies. Providers are expected to exercise their medical judgement in providing the most appropriate care for their patients.